[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medialis Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100610549","global-overweight-and-obese-globe-patient-registry-development-and-implementation-of-disease-specific-severity-quality-of-life-and-cost-instruments-100610549",false,"NCT07229027","Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.","GLOBE","Inclusion Criteria:\n\n* Patient group\n\n  1. Patient is aged ≥18 years at the time of survey completion.\n  2. Patient has a BMI over 25 (self-reported)\n  3. Patient is willing to participate in all study activities.\n  4. Patient is able to read, write, and converse in English.\n* Healthcare professional participant must meet the following criteria for inclusion in the study:\n\n  1. HCP is aged ≥18 years at the time of survey completion.\n  2. HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25\n  3. HCP is willing to participate in all study activities.\n  4. HCP is able to read, write, and converse in English.\n\n     Exclusion Criteria:\n\nA participant who meets any of the following criteria will be excluded from the study:\n\n1. Participants do not have the cognitive capacity to provide informed consent.\n2. Participants with severe co-morbidity that might affect study participation.",true,"ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","60 Months","OBSERVATIONAL","We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.",[26,27],"Overweight (BMI > 25)","Obesity & Overweight","RECRUITING","2025-11-13",{"date":31,"type":32},"2025-11-14","ACTUAL",{"date":34,"type":32},"2025-11-01",{"date":36,"type":21},"2026-08",{"name":38,"class":39},"Medialis Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100448775","medical-affairs-pharmaceutical-physician-work-related-quality-of-life-mappwrqol-instrument-development-and-patient-registry-mappwrqolreg-100448775","NCT05123846","Medical Affairs Pharmaceutical Physician Work-related Quality of Life (MAPPWrQoL) Instrument Development and Patient Registry (MAPPWrQoLReg)","Inclusion Criteria:\n\nPhase one and Phase two: Participants will be eligible to take part in Phase One based on the following criteria:\n\n* Qualification as a Medical Affairs Pharmaceutical Physician (qualified by medical degree).\n* Previous or current work experience within a pharmaceutical company (industry-based).\n* The participant can provide informed consent.\n* The participant can read, write, and converse in English.\n* The participant can comply with the study schedule.\n* 18 years and above.\n\nExclusion Criteria:\n\n* Non-industry based Medical Affairs Pharmaceutical Physicians\n* Not able to comply with the study schedule\n* Not able to read, write, and converse in English.",{"count":48,"type":21},180,"Existing evidence has shown that medical affairs pharmaceutical physicians (MAPPs), are a core function within the pharmaceutical industry. Despite their expertise, there are ongoing concerns about recognition and respect for the MAPP's role within the pharmaceutical industry. Anecdotal evidence further suggests that this lack of recognition and respect for the valuable contribution of this specialised group of medical doctors may impact their quality of life, resulting in stress, anxiety, depression and occupational burnout. Hence, participants are likely to use NHS services as patients, when experiencing the physical, mental, and emotional issues associated with occupational burnout, an internationally recognised condition (ICD-11 code QD85) resulting from chronic occupational stress.\n\nThis observational study will recruit participants to contribute data to creating a MAPP work-related participant-reported outcome measure on the impact of work-related performance on quality of life (QoL). The created MAPP work-related participant-reported measure will be used longitudinally with study participants to measure their QoL monthly for 12 months. In total, up to 180 Medical Affairs Pharmaceutical Physicians are expected to be recruited to the study. The study will be conducted in two main phases, involving three online surveys.",[51],"Quality of Life",[51,53,54,55,56,57],"Jandhyala Method","Medical Affairs","Occupational burnout","Stress","Anxiety","2023-10-19",{"date":60,"type":32},"2023-10-23",{"date":62,"type":32},"2021-11-03",{"date":64,"type":21},"2026-10",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100407514","post-acute-covid-19-quality-of-life-pac-19qol-tool-development-and-patient-registry-pac-19qolreg-100407514","NCT04586413","Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)","Phase One\n\nInclusion Criteria:\n\n* The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection\n* The participant is aged 18 years or older\n* The participant is capable of providing informed consent\n* The participant can read, write and converse in English\n* The participant can comply with the study schedule\n\nExclusion Criteria:\n\n* The participant does not have a confirmed COVID-19 test or antibody test\n* The participant is aged under 18 years\n* The participant is not capable of giving informed consent\n* The participant is unable to read, write and converse in English\n* The participant is unable to comply with study schedule data collection\n\nPhase Two\n\nInclusion Criteria:\n\n* The participant has had either a confirmed COVID-19 test while infected or a confirmed COVID-19 antibody test post-infection or a clinical diagnosis of COVID-19\n* The participant is aged 18 years or older\n* The participant is capable of providing informed consent\n* The participant can read, write and converse in English\n* The participant can comply with the study schedule\n\nExclusion Criteria:\n\n* The participant does not have a confirmed COVID-19 test or antibody test or clinical diagnosis of COVID-19\n* The participant is aged under 18 years\n* The participant is not capable of giving informed consent\n* The participant is unable to read, write and converse in English\n* The participant is unable to comply with study schedule data collection",{"count":73,"type":21},100,"Coronavirus Disease 2019 (COVID-19) is a newly emerged disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic is having a large impact on the mental and physical health of patients, yet data on the quality of life of post-COVID-19 patients is lacking. There are currently no post-COVID-19 specific measures for quality of life, particularly none which include the views of post-COVID-19 patients themselves. This observational study will recruit participants to contribute their preferences to the creation of a post-COVID-19 specific patient-reported measure on post-COVID-19 quality of life. Participants will be split into three groups: those who were not hospitalised; those who were hospitalised but not in intensive care units; and those who were hospitalised and in intensive care units. The creation of this measure will form phase 1 of the study, with 30-60 participants (10-20 in each group above) recruited to complete online surveys to find out their preferences of areas of life to include in such a measure. This will involve 3 online surveys, 1) to ask which areas of life they feel are impacted and how; 2) to find consensus about the areas to be included; 3) to weight the relevance of these areas in relation to each other. In phase 2 recruitment will open to additional participants and all participants will be asked to complete the finalised post-COVID-19 quality of life measure once a month for 12 months, aiming for a minimum of 100 participants at this stage. All participants will also be asked to complete a demographic questionnaire to inform the analysis of the data.",[76],"Covid19",[76,51,78],"Post-Covid19",{"date":60,"type":32},{"date":81,"type":32},"2020-10-07",{"date":83,"type":21},"2028-10",{"name":38,"class":39},""]